Background and aim The population-based incidence rate of drug-induced liver injury (DILI) in the USA is not known. The Drug-Induced Liver Injury Network (DILIN) accrues cases of hepatotoxicity due to medications and herbal and dietary supplements (HDS) from limited geographical areas. The current analysis was an ancillary study of DILIN aimed at determining the annual incidence of DILI in the USA on a population basis, through surveillance in the state of Delaware. Methods At the outset of the study, there were 41 gastroenterologists in the state of Delaware and all agreed to participate in surveillance for DILI, which comprised active reporting of suspected cases to the DILIN. The gastroenterologists underwent training in the diagnosis of DILI and were provided with DILIN inclusion criteria. Only cases that met the DILIN laboratory inclusion criteria in 2014 were included in the incidence calculation, and these patients were invited to participate in the DILIN Prospective Study. The number of suspected cases that met inclusion criteria served as the numerator and the 2014 Delaware adult population as the denominator. Results During 2014, 23 patients were identified by the surveillance network, 20 of whom met DILIN laboratory inclusion criteria, leading to an incidence of 2.7 cases of DILI per 100,000 adult residents [95% confidence interval (CI) 1.5-3.9 per 100,000]. Fourteen subjects agreed to participate in the DILIN; six declined. Among enrolled cases, the mean age was 51 years, 57% were women, and 71% were white. Eight cases were attributed to antibiotics (36%) and other drugs (21%) and six to HDS (43%). The pattern of injury was hepatocellular in all HDS cases, but only 50% of conventional drug cases (p = 0.05), which more commonly presented with eosinophilia (p = 0.47) and higher alkaline phosphatase levels (p = 0.05). Half of patients were jaundiced, none developed liver failure, and all recovered without the need for transplantation. Conclusion Prospective, gastroenterologist-based surveillance for suspected DILI in Delaware yielded an incidence of 2.7 cases per 100,000 adults in 2014; this is the first prospective estimate of DILI for the USA. Because surveillance was limited to subspecialists, the actual incidence of DILI is likely to be higher. These findings provide a benchmark statistic for the epidemiology of DILI in the United States, to be refined with expansion of the surveillance period.
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Introduction
For most drugs, the risk of drug-induced liver injury (DILI), which can be associated with impairment of liver function, disability, or death, is a rare event. It has been estimated to occur with a frequency of between one in 10,000 and one in 100,000 patients exposed [1] . The actual frequency of DILI in the population may be much higher than these estimates, as underreporting of drug reactions of any kind by practitioners is common [2] . A 2002 study gave insight into the extent of underreporting of DILI; when a trained cohort of physicians in France performed surveillance for DILI, an incidence rate of 14 cases per 100,000 inhabitants per year was found, which was 16 times the spontaneous reporting rate [3] . Studies using retrospective approaches have been performed to give insight into DILI epidemiology. A group of investigators in Sweden identified a DILI incidence of 2.3 per 100,000 inhabitants per year, with antibiotics being the most common class of agents implicated [4] . This was similar to an incidence of 2.4 per 100,000 from a study in the UK [5] . A 2015 retrospective cohort study of druginduced acute liver failure in an integrated health care system in the USA found an incidence of 1.61 events per million person-years [6] . In a single center, non-population-based experience in the USA, 0.8% of 4039 patients referred to a hepatology clinic for acute or chronic liver dysfunction had DILI [7] . Finally, of 732 patients with jaundice presenting to a US hospital, 29 (4%) had DILI, but only five (0.7%) had non-acetaminophen (idiosyncratic) injury [8] . In the only published prospective cohort population-based study, Björnsson et al. found a DILI incidence of 19.1 cases per 100,000 in Iceland [9] . No such population-based data exist in the USA. The disparate findings between the retrospective and prospective cohort studies, as well as the lack of US epidemiologic data for DILI, highlight the need to better understand its epidemiology. Population-based estimates can clarify the scope of the problem and help to determine the need for research and, in the case of herbal and dietary supplement (HDS)-induced injury, regulation.
The Drug-Induced Liver Injury Network (DILIN) is a multi-center research network charged with improving the understanding of the etiologies, risk factors, and outcomes of DILI in the USA [10] . As part of the DILIN study, we aimed to determine the annual incidence of DILI in Delaware, a state chosen because of its representative demography and established relationship with DILIN, by using active surveillance through gastroenterology practices in the state.
Methods
The DILIN sponsored the current study to ascertain the epidemiology of DILI in the state of Delaware for several reasons. First, there was no large referral liver center in the state. As a result, patients and referring primary care providers caring for patients with symptoms of DILI were likely to refer to in-state gastroenterologists. Second, the relatively small number of gastroenterologists within Delaware made frequent contact between the investigator team and the providers' offices for case identification feasible. Third, a DILIN clinical site maintained two offices in Delaware (Wilmington and Dover), which provided rapid access for patients entering the study for enrollment procedures. Finally, the population of Delaware closely matched the demography of the US general population. Table 1 shows the comparative demographics between Delaware and the US population.
At the outset of the study, there were 41 gastroenterologists in the state, as identified through Google searches and proprietary provider databases; when approached, all agreed to participate in surveillance for DILI. Surveillance comprised active reporting of suspected cases by the gastroenterologists to DILIN between and including January 2014 and December 2014. Gastroenterologists underwent training in the recognition and diagnosis of DILI through a face-to-face session with a DILIN investigator (VN), and were provided with DILIN inclusion criteria, which included the following: (1) aspartate or alanine aminotransferase (ALT or AST) levels above five times or alkaline phosphatase (AP) levels above two times the upper limit of the normal range (ULN) on two consecutive occasions; and (2) any elevation in ALT, AST, or AP with a total bilirubin (TB) of C2.5 mg/dL or coagulopathy with an international normative ratio (INR) of [1.5 in the absence of other diagnosis. Regular electronic and fax reminders of the study and entry criteria were provided. Only cases that met the DILIN laboratory inclusion criteria during 2014 were included in the calculation of incidence, and all patients were invited to enroll in the DILIN Prospective Study. Those who enrolled into the DILIN study were interviewed and examined by a DILIN investigator (VN); all potential causes of liver injury were excluded. Through the DILIN adjudication process, the likelihood of DILI was assessed, as was the specific drug cause for liver injury [10] . The number of suspected cases that met inclusion criteria served as the numerator and the 2014 Delaware adult ([18 years) population (729,779) as the denominator, with the corresponding 95% confidence intervals (CIs) also computed. Gastroenterologists were offered nominal practice management fees to offset the clerical work of referring suspect cases to the research team.
For those enrolled in the DILIN study, comparisons of characteristics were made between those attributed to conventional medications and those due to HDS. For continuous variables, the Wilcoxon test was used for comparison of groups, while the Chi-square test (or Fisher exact test for situations with small frequencies) was used for comparison of categorical variables. A p value of 0.05 or less is considered statistically significant. Informed consent was obtained from all individual participants included in the study.
Results
A total of 23 patients were identified by the surveillance network during the 12-month study period; 20 of 23 patients met DILIN laboratory inclusion criteria, leading to a yearly DILI incidence of 2.7 cases per 100,000 adult residents (95% CI 1.5-3.9 per 100,000). Fourteen of the 20 individuals who met entry criteria signed consent to enroll in the DILIN study; six declined. More detailed information was available from the enrolled cases; the mean age was 51 years, 57% were women, and 71% were white.
Liver injury for eight of the 14 cases enrolled in the DILIN were attributed to conventional medications (antibiotics 36% and other drugs 21%) and six to HDS (43%). All HDS cases and 50% of conventional drug cases exhibited a hepatocellular pattern of liver injury (p = 0.05) as defined by an R ratio of[5 (R ratio = [ALT value/ALT ULN] 7 [AP value/ AP ULN]). Both initial and peak ALT and AST values were higher in the HDS-induced injury cases, whereas AP levels were higher in the conventional medication-induced injury cases (p = 0.05) ( Table 2 ). Medication-associated DILI cases presented more commonly with eosinophilia (p = 0.47) and elevated AP (p = 0.05) than the HDS cases. Time from onset of DILI to a 50% reduction in TB was more rapid with the conventional drug-associated injury (12 days) than with HDS injury (25 days) (p = 0.05). Fifty percent of patients with HDS injury were symptomatic for more than 4 weeks, as compared with 25% due to drugs, although this finding was not statistically significant. Sixty-four percent of patients were hospitalized, 50% were jaundiced, none developed acute liver failure, all patients recovered, and none required liver transplantation. Additional characteristics for the 14 enrolled cases can be found in Supplemental Table 1 .
Discussion
This study is the first to report a population-based estimate of the frequency of DILI in an American cohort. We found an incidence of 2.7 cases per 100,000 adults in the year 2014. From the subset of cases enrolled into the DILIN, we found that the majority of DILI cases were attributed to conventional medications, but liver injury induced by HDS accounted for almost half of cases and antibiotics were the most frequent class of implicated medications. These findings are in keeping with our previous report, that HDS comprise the second most common culprit responsible for liver injury in the DILIN cohort [13] . The clinical patterns of injury, either hepatocellular, cholestatic, or mixed, are indicative of the typical pattern of injury associated with the implicated antibiotics, rather than a reflection of all conventional medications. An accurate statistic for DILI epidemiology is important for several reasons. It defines the scope of the problem and thus its impact on the population. This allows for comparison to other preventable and non-preventable negative health occurrences, such as disease-specific attributable morbidity and mortality, overdose, poisonings, and motor vehicle accidents. The chasm between the epidemiologic estimates reported in retrospective studies, which were similar to our study, and the prospective studies in France and Iceland begs further understanding to determine the impact of underreporting and to develop means of more complete DILI reporting. Finally, having credible population-based data gives researchers, pharmaceutical companies, and regulators stronger rationale to allocate resources to drug-and HDS-injury prevention and treatment. This is particularly important in the case of injury due to HDS, as current regulations are not based upon proof of safety to the consumer. Arguably, that liver injury resulting from HDS is more common than some conventional pharmaceuticals should be reason enough to revisit the adequacy of current regulations.
Using Delaware for this epidemiologic study was a matter of convenience; its demographic similarity to the US population made it a relevant population-based cohort. Still, our findings represent a much lower incidence rate than was seen in Iceland and France. Because many cases might be identified and cared for by primary care or nongastroenterology providers without having been referred to a gastroenterologist participating in the surveillance network, the true incidence of DILI in the US population is likely to be higher. Further, our surveillance network did not include hospitals, and therefore patients with severe liver injury or acute liver failure were not detected. Therefore, our statistic must be viewed as the lower limit of reality. As such, our findings provide a benchmark statistic for the epidemiology of DILI in the USA, to be refined with expansion of the surveillance period. Based on preliminary findings of a prospective surveillance network limited to gastroenterologists in the state of Delaware, the incidence of liver injury due to conventional medications or HDS is at least 2.7 cases per 100,000. The true incidence is likely higher and can only be determined by expansion and continuation of surveillance. HDS continue to be a common cause of injury among those affected.
